(lp0
S'Earnings Reaction History: TrovaGene, Inc., 75.0% Follow-Through Indicator, 7 ... Nasdaq - Mar 15, 2017 TrovaGene, Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement.'
p1
aS'Trovagene to Announce Fourth Quarter and Year End 2016 Financial Results and ... PR Newswire  - Mar 1, 2017 SAN DIEGO, March 1, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will report financial results for the fourth quarter and year ended December 31, 2016&nbsp;...'
p2
aS'Trovagene and Boreal Genomics Announce Strategic Partnership PR Newswire  - Nov 30, 2016 SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, today announced it has entered into a long-term Supply and Distribution Agreement with Boreal Genomics,&nbsp;...'
p3
aS'Trovagene Announces Broadening Network of Commercial Distributors PR Newswire  - Jan 12, 2017 SAN DIEGO, Jan. 12, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  technologies, today announced that it has signed agreements with seven strategic partners across Europe and the Middle East for&nbsp;...Trovagene inks seven deals for commercialization of liquid biopsy tests ex-US - Seeking Alpha'
p4
aS'Trovagene announces a reorganization to accelerate global distribution of ... PR Newswire  - Dec 13, 2016 SAN DIEGO, Dec. 13, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, announced today that it will increase its focus on the global distribution of kits and systems to clinical&nbsp;...Trovagene to Focus More on Liquid Biopsy Testing Market - Yahoo Finance'
p5
aS'Trovagene to Attend the 29th Annual ROTH Conference PR Newswire  - Feb 28, 2017 SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, is scheduled to attend the 29th Annual ROTH Conference, March 12-15, 2017, at the Ritz Carlton Laguna&nbsp;...'
p6
aS"Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments PR Newswire  - Nov 9, 2016 SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of circulating tumor DNA  molecular diagnostics, today reported its financial results and accomplishments for the third quarter ended September 30, 2016.TrovaGene's  CEO Bill Welch on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha"
p7
aS"Stock's Stunning Activities: TrovaGene, Inc.  Normangee Star - 9 hours ago Working capital drops significantly Trovagene, Inc. has witnessed a decline in the working capital over the past year.Trovagene nabs rights to leukemia candidate from Nerviano Medical - Seeking AlphaTrovaGene Inc  Downgraded to Underweight at Piper Jaffray Companies - The Cerbat Gem"
p8
aS"Analyst's Proposition on TrovaGene, Inc. , The Goldfield Corporation  The USA Commerce - Mar 17, 2017 Presently TrovaGene, Inc.  stock have an ABR of 1.67. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.Time To Get Cautious?  TrovaGene, Inc. , The Goldfield Corporation  - USA Commerce Daily"
p9
aS"Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands ... PR Newswire  - Feb 1, 2016 SAN DIEGO, Feb. 1, 2016 /PRNewswire/ -- Trovagene, Inc. , a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with FedMed, Inc.  establishing health benefit access to&nbsp;...Could This Be the Turning Point for TrovaGene? - 24/7 Wall St.Here's Why TrovaGene  Stock is Soaring Today - TheStreet.com"
p10
a.